These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38004432)

  • 21. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
    Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
    Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
    Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
    Stamatellos VP; Papazisis G
    Curr Rev Clin Exp Pharmacol; 2023; 18(1):39-50. PubMed ID: 35418296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac safety profile of type II kinase inhibitors: Analysis of post-marketing reports from databases of European Medicine Agency & World Health Organization.
    Khurana A; Arora MK; Dubey H
    Daru; 2023 Dec; 31(2):107-118. PubMed ID: 37221442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System.
    Barbieri MA; Sorbara EE; Russo G; Cicala G; Franchina T; Santarpia M; Silvestris N; Spina E
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
    Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
    CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants.
    Bove R; Hellwig K; Pasquarelli N; Borriello F; Dobson R; Oreja-Guevara C; Lin CJ; Zecevic D; Craveiro L; McElrath T; Vukusic S
    Mult Scler Relat Disord; 2022 Aug; 64():103963. PubMed ID: 35753176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregnancy and multiple sclerosis: an update.
    Varytė G; Arlauskienė A; Ramašauskaitė D
    Curr Opin Obstet Gynecol; 2021 Oct; 33(5):378-383. PubMed ID: 34310364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.
    Alroughani R; Altintas A; Al Jumah M; Sahraian M; Alsharoqi I; AlTahan A; Daif A; Dahdaleh M; Deleu D; Fernandez O; Grigoriadis N; Inshasi J; Karabudak R; Taha K; Totolyan N; Yamout BI; Zakaria M; Bohlega S
    Mult Scler Int; 2016; 2016():1034912. PubMed ID: 28078140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.
    Noseda R; Bedussi F; Gobbi C; Zecca C; Ceschi A
    Cephalalgia; 2021 Jun; 41(7):789-798. PubMed ID: 33435709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
    Caldito NG; Shirani A; Salter A; Stuve O
    Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Women with Multiple Sclerosis Planning Pregnancy.
    Krysko KM; Bove R; Dobson R; Jokubaitis V; Hellwig K
    Curr Treat Options Neurol; 2021; 23(4):11. PubMed ID: 33814892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.
    Wallerstedt SM; Brunlöf G; Sundström A
    Drug Saf; 2011 Aug; 34(8):669-82. PubMed ID: 21751827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-Marketing Surveillance of Statins-A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance.
    Pop G; Farcaș A; Butucă A; Morgovan C; Arseniu AM; Pumnea M; Teodoru M; Gligor FG
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36558987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
    Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
    Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety concerns reported by consumers, manufacturers and healthcare professionals: A detailed evaluation of opioid-related adverse drug reactions in the FDA database over 15 years.
    Andreaggi CA; Novak EA; Mirabile ME; Sampathkumar S; Gray MP; He M; Kane-Gill SL
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1627-1635. PubMed ID: 32851782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.